Globe Life is an insurance holding company that sells life and supplemental health insurance mainly to middle-income households in the United States. It reaches customers through direct-to-consumer marketing, agencies and employer or association channels. Revenue comes from premiums paid by policyholders and from investment income earned on the assets backing its policy obligations, so claims experience and investment returns shape its results.
Trailing twelve-month revenue stands at $6.2 billion. Revenue growth over three years averaged 4.7% a year. Operating margin is 26.4% and return on invested capital is 15%. It pays a dividend with a yield of 0.7%. The X-Ray Score is 49 out of 100. These figures describe past results as reported and are a factual snapshot, not a forecast. Some measures, such as margins for real estate trusts and banks, are defined differently from those of industrial firms, so comparisons should be made with care.
52-wk range $127.85 – $191.55Volume 1,736,006Daily, split-adjusted
Vitals
Market cap$13.3B
52-week range$127.85 – $191.55
Volume (last day)1,736,006
P/E (TTM)11.2
EBIT / EV yield10.4%
Free-cash-flow yield9.3%
Dividend yield0.7%
Revenue (TTM)$6.2B
Net income (TTM)$1.2B
Operating margin26.4%
Return on capital15.3%
Debt incl. leases$2.9B
Cash & securities$455M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$150middle half of models $138 – $167
Fair−11.2% to fair value
Average of the 4 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Medium, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Financials peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
ValuationWeak
42/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield10.4%
Free-cash-flow yield9.3%
Fair value vs price0.9×
GrowthWeak
42/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)4.7%
EPS growth (3y)15.9%
Growth consistency100%
ProfitabilityFair
58/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital15.3%
Operating margin26.4%
Financial healthFair
51/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA1.5×
Interest cover11.6×
DividendsWeak
48/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.7%
Dividends vs free cash flow8%
Dividend growth2.2%
Quarterly results: last 6 quarters
+4.5%Mar '25
+2.8%Jun '25
+4.0%Sep '25
+3.6%Dec '25
+5.3%Mar '26
+8.0%Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.6B, diluted EPS $3.65.
Other Life & Health Insurance companies by X-Ray Score.
SWOT analysis: Globe Life Inc.
Strengthsinside the company
Operating margin of 26.4% is well above the 8.3% median of industry peers, a sign of pricing power or lower costs.
Earnings per share have compounded at 15.9% a year over three years.
Free cash flow equals 9.3% of the market value, which funds dividends, buybacks or debt paydown.
Passes 8 of the 9 Piotroski tests, which points to improving profitability, funding and efficiency.
Weaknessesinside the company
No clear weakness in the figures we track.
Opportunitiesvaluation and setting
Trades at 11.0x earnings, 21% below the 13.8x median of industry peers.
Our Market Compass rates the backdrop for Financials as favourable.
Threatsvaluation and setting
No specific threat is flagged by our checks; general market and interest-rate risk still applies.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare GL with peers and sector
Medians of 4 Life & Health Insurance peers and of 70 Financials stocks in our universe.
Largest peers (X-Ray Score): MET56, AFL35, PFG37, PFH55.
Metric
GL
Peers
Sector
X-Ray Score (out of 100)
49
46
50
Valuation
42
63
52
Growth
42
9
54
Profitability
58
47
48
Financial health
51
52
50
Dividends
48
44
54
Sector leaders: highest X-Ray Score in Financials
GL ranks #44 of 71 in Financials and #3 of 5 in Life & Health Insurance by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for GL
Each factor is rated by where GL stands among the 71 Financials stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 1 Good · 5 Average · 2 Bad of 8Growth: 0 · 1 · 2Profitability: 0 · 2 · 0Valuation: 1 · 2 · 0
Factor
GL
Rating
Sector median
Own 5-year median
Against own history
Growth
Revenue growth, 3 years a year
+4.7%
Badbeats 27%
+8.3%
–
–
Revenue growth, last year
+3.7%
Badbeats 23%
+6.9%
+4.2%
≈ In line
EPS growth, 3 years a year
+15.9%
Averagebeats 62%
+12.7%
–
–
Profitability
Net margin
19.6%
Averagebeats 45%
21.8%
18.5%
≈ In line
Return on equity
19.7%
Averagebeats 66%
15.7%
21.6%
≈ In line
Valuation
P/E ratio
11.0x
Goodbeats 76%
13.8x
9.9x
≈ In line
Price / book
2.2x
Averagebeats 52%
2.2x
2.6x
▲ Better
Price / sales
2.1x
Averagebeats 64%
3.1x
1.9x
≈ In line
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings), and banks and insurers are rated only on the factors that apply to them. A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 3 Good · ● 6 Average · ● 4 Bad
Cash quality
Earnings backed by cashAverage
Free-cash-flow yieldGood
Risk models
Piotroski F-ScoreGood
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyGood
Balance sheet
Net debt / EBITDAAverage
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 47/100.
Financials
FY21
FY22
FY23
FY24
FY25
Revenue
$5.1B
$5.2B
$5.4B
$5.8B
$6.0B
Operating income
$1.2B
$1.2B
$1.3B
$1.5B
$1.6B
Net income
$1.0B
$894M
$971M
$1.1B
$1.2B
Operating cash flow
$1.4B
$1.4B
$1.5B
$1.4B
$1.4B
Operating margin
24.0%
22.7%
23.2%
25.2%
26.3%
Free cash flow
$1.4B
$1.4B
$1.4B
$1.3B
$1.3B
Diluted EPS
$9.99
$9.04
$10.07
$11.94
$14.07
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
8 bullish · 4 neutral · 4 bearish
Weekly
Bullish
7 bullish · 1 neutral · 4 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
SMA 10
167.5
Bullish
EMA 10
168.0
Bullish
SMA 20
166.6
Bullish
EMA 20
167.9
Bullish
SMA 50
170.3
Bearish
EMA 50
169.5
Bearish
SMA 100
172.5
Bearish
EMA 100
168.0
Bullish
SMA 200
158.7
Bullish
EMA 200
160.3
Bullish
Oscillators (daily)
RSI (14)
50.37
Neutral
MACD (12, 26)
-0.41
Bearish
Momentum (12)
1.28
Bullish
Stochastic %K (14)
72.45
Neutral
Williams %R (14)
-27.55
Neutral
CCI (20)
-15.78
Neutral
Pivot points (classic, last session)
S3
156.7
S2
159.1
S1
163.8
Pivot
166.2
R1
170.8
R2
173.3
R3
177.9
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.26 USD
Yield on today's price
0.75%
Frequency
Quarterly
Next ex-dividend date
Not announced
Ex-dividend date
Amount per share
0.3300
0.3300
0.3300
0.2700
0.2700
0.2700
0.2700
0.2400
0.2400
0.2400
0.2400
0.2250
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
The eight funds with the largest weight in GL among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
GL stock splits
GL has split its stock 4 times since 1992. The latest was a 3-for-2 split on 2 Jul 2014.